Assignee
SHATTUCK LABS INC
US·21 granted patents·31 pending applications·43 citations·filing 2018–2025
Top patents by PatentIndex Score
52 records- 0197US10988517B2Heterodimeric proteins for modulating gamma delta T cellsSHATTUCK LABS INC·Filed 2020·Granted Apr 27, 2021·4 cites·18 claims
- 0296US11834488B2VSIG8-based chimeric proteinsSHATTUCK LABS INC·Filed 2021·Granted Dec 5, 2023·2 cites·19 claims
- 0396US11643447B2Heterodimeric proteins for modulating gamma delta T cellsSHATTUCK LABS INC·Filed 2022·Granted May 9, 2023·2 cites·19 claims
- 0496US10899817B2TIGIT- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2020·Granted Jan 26, 2021·3 cites·20 claims
- 0595US10995127B2Heterodimeric proteins and uses thereofSHATTUCK LABS INC·Filed 2019·Granted May 4, 2021·8 cites·14 claims
- 0694US12319742B1Antibodies that bind TNFRSF25SHATTUCK LABS INC·Filed 2025·Granted Jun 3, 2025·1 cites·17 claims
- 0794US11780897B2Heterodimeric proteins and uses thereofSHATTUCK LABS INC·Filed 2021·Granted Oct 10, 2023·2 cites·20 claims
- 0894US10927159B2TIGIT- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2020·Granted Feb 23, 2021·2 cites·26 claims
- 0993US11896618B2FLT3L-based chimeric proteinsSHATTUCK LABS INC·Filed 2020·Granted Feb 13, 2024·2 cites·3 claims
- 1091US11098093B2Heterodimeric proteins for modulating gamma delta T cellsSHATTUCK LABS INC·Filed 2020·Granted Aug 24, 2021·2 cites·16 claims
- 1190US11332509B2Methods of making and using extracellular domain-based chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted May 17, 2022·2 cites·20 claims
- 1290US10513548B2CSF1R-based chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted Dec 24, 2019·3 cites·16 claims
- 1389US12492236B2Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Granted Dec 9, 2025·0 cites·6 claims
- 1489US2024368242A1Methods of making and using extracellular domain-based chimeric proteinsSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 1588US12145975B2Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Granted Nov 19, 2024·0 cites·1 claims
- 1688US11267857B2CSF1R-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Granted Mar 8, 2022·2 cites·18 claims
- 1788US11192934B2VSIG8-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Granted Dec 7, 2021·2 cites·10 claims
- 1888US2024190939A1Tigit- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 1987US11267856B2CSF1R-CD40L chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted Mar 8, 2022·2 cites·14 claims
- 2087US10780121B2FLT3L-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Granted Sep 22, 2020·2 cites·7 claims
- 2187US2025066446A1Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 2287US2025145681A1Fusion proteins for the treatment of cardiometabolic diseasesSHATTUCK LABS INC·Filed 2024·Application pending·0 cites
- 2386US11192933B2VSIG8-based chimeric proteinsSHATTUCK LABS INC·Filed 2018·Granted Dec 7, 2021·2 cites·10 claims
- 2484US2024067698A1Vsig8-based chimeric proteinsSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 2583US12071465B2Methods of making and using extracellular domain-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Granted Aug 27, 2024·0 cites·20 claims
- 2681US2022227831A1Tigit- and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 2777US2023220030A1Heterodimeric proteins and uses thereofSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 2876US2022144909A1Csf1r-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 2973US12460010B2Antibodies that bind TNFRSF25SHATTUCK LABS INC·Filed 2025·Granted Nov 4, 2025·0 cites·14 claims
- 3071US2024011101A1Method of determining resistance to checkpoint inhibitor therapiesSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 3171US2024016892A1Methods of treating cancer using tigit-and light-based chimeric proteinsSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 3268US2023045794A1Nk cell-directed chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 3368US2024122983A1Flt3l-based chimeric proteinsSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 3465US2021379153A1Combination therapies comprising sirp alpha-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 3565US2022025000A1Heterodimeric proteins for modulating gamma delta t cellsSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 3665US2021309744A1Combination therapies comprising pd-1-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 3762US2020399344A1Nk cell-directed chimeric proteinsSHATTUCK LABS INC·Filed 2020·Application pending·0 cites
- 3862US2025223313A1Methods of contaminant removal from protein isolatesSHATTUCK LABS INC·Filed 2023·Application pending·0 cites
- 3961US2023048633A1Tgfbr2-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4060US2024141014A1Mutant pd-1 extracellular domainsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4160US2024299492A1Combination therapies with sirp alpha-based chimeric proteinsSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4258US2023408523A1Methods of identifying gamma delta t cell-modulating agentsSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 4358US2024148828A1Gamma delta t-cell costimulationSHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4456US2023416333A1Homodimeric and heterodimeric proteins comprising butyrophilinSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 4555US2025345406A1Chimeric proteins in autoimmunitySHATTUCK LABS INC·Filed 2022·Application pending·0 cites
- 4654US2021179689A1Combination therapies comprising tim-3-based chimeric proteinsSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 4754US2021324041A1Combination therapiesSHATTUCK LABS INC·Filed 2019·Application pending·0 cites
- 4853US2022259281A1Chimeric protein expressing t-cellsSHATTUCK LABS INC·Filed 2020·Application pending·0 cites
- 4952US2025320268A1Clinical dosing of sirp1a chimeric proteinSHATTUCK LABS INC·Filed 2021·Application pending·0 cites
- 5051US2022185863A1Combination therapiesSHATTUCK LABS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →